Go Pro
→ First Look: Elon’s “Starphone” (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$98.86
+0.9%		$102.47
$28.16
▼
$155.29
$1.46B3.82316,783 shs12,601 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-2.15%-2.46%-21.44%+0.36%+188.20%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$98.86
+0.9%		$102.47
$28.16
▼
$155.29
$1.46B3.82316,783 shs12,601 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-2.15%-2.46%-21.44%+0.36%+188.20%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.50
Moderate Buy$197.50101.67% Upside

Current Analyst Ratings Breakdown

Latest INBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
9/11/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/27/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
8/24/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$245.00
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.30M1,108.87N/AN/A$0.55 per share178.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$140.05M-$8.88N/AN/AN/AN/A-563.90%-83.48%11/13/2026 (Estimated)

Latest INBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$2.28-$2.34-$0.06-$2.34N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/A
5.07
5.07

Institutional Ownership

CompanyInstitutional Ownership
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%

Insider Ownership

CompanyInsider Ownership
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
18.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
11014.72 million12.03 millionOptionable

Recent News About These Companies

Inhibrx logo overlaid on a laboratory scene with vials, pipettes, and a computer screen showing a protein model.
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
...
 |  marketbeat.comhttps://www.marketbeat.com/articles/inhibrxs-insider-buying-adds-fuel-to-a-high-short-interest-biotech-setup/
INBX CEO buys 10,000 shares in September filing
October 1 at 7:02 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31074003
Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Mark Lappe Acquires 5,500 Shares
September 30 at 5:10 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068421
Inhibrx Biosciences (NASDAQ:INBX) Stock: Insider Mark Lappe Buys 4,500 Shares
September 30 at 5:10 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31068411
Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating
September 29 at 9:56 AM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/inhibrx-biosciences-inbx-faces-pipeline-110851641.html
Inhibrx Biosciences (NASDAQ:INBX) CEO Acquires $453,420.00 in Stock
September 29 at 4:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-inbx-insider-buying-and-selling-2026-09-29/
Inhibrx Biosciences (NASDAQ:INBX) CEO Mark Lappe Buys 4,500 Shares of Stock
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-inhibrx-biosciences-nasdaq-inbx-ceo-mark-lappe-buys-4500-shares-of-stock-2026-09-28/
Inhibrx Biosciences (NASDAQ:INBX) CEO Mark Lappe Purchases 5,500 Shares of Company Stock
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-inhibrx-biosciences-nasdaq-inbx-ceo-mark-lappe-purchases-5500-shares-of-company-stock-2026-09-28/
Inhibrx Biosciences (NASDAQ:INBX) Shares Climb 3.7% - Here's Why
September 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-inhibrx-biosciences-nasdaq-inbx-shares-climb-37-heres-why-2026-09-28/
Inhibrx Biosciences stock reports stronger cancer study data
September 25, 2026  |  ad-hoc-news.deA
Inhibrx Biosciences stock reports a 48.3 percent response rate
September 24, 2026  |  ad-hoc-news.deA
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
September 24, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/inhibrx-cancer-drug-nearly-doubled-170714117.html
Inhibrx Biosciences (NASDAQ:INBX) Director Jon Faiz Kayyem Acquires 5,000 Shares of Stock
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044538
Inhibrx Biosciences (NASDAQ:INBX) Director Jon Faiz Kayyem Buys 5,000 Shares
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-inhibrx-biosciences-nasdaq-inbx-director-jon-faiz-kayyem-buys-5000-shares-2026-09-23/
Inhibrx Biosciences (NASDAQ:INBX) Trading Down 8.8% - Here's What Happened
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-inhibrx-biosciences-nasdaq-inbx-trading-down-88-heres-what-happened-2026-09-23/
Inhibrx Biosciences stock gains on insider buying and trial progress
September 22, 2026  |  ad-hoc-news.deA
Inhibrx Biosciences stock gains institutional support as Bank of America invests
September 20, 2026  |  ad-hoc-news.deA
10,170 Shares in Inhibrx Biosciences, Inc. $INBX Bought by Tidal Investments LLC
September 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-10170-shares-in-inhibrx-biosciences-inc-inbx-bought-by-tidal-investments-llc-2026-09-20/
Bank of America Corp DE Makes New $79.70 Million Investment in Inhibrx Biosciences, Inc. $INBX
September 20, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-makes-new-7970-million-investment-in-inhibrx-biosciences-inc-inbx-2026-09-20/
Insider Buying: Inhibrx Biosciences (NASDAQ:INBX) Director Buys 5,000 Shares of Stock
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-buying-inhibrx-biosciences-nasdaq-inbx-director-buys-5000-shares-of-stock-2026-09-17/
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
September 15, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/09/15/inhibrx-founder-and-ceo-mark-lappe-buys-25-000-shares-for-usd2-6-million-what-does-his-confidence-tell-investors/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Stacks of coins rising on a desk beside a computer with an upward stock chart, with a blurred city skyline behind.
3 Dividend Kings to Buy While They’re Still Beaten Down
By Thomas Hughes | September 14, 2026
Inhibrx logo overlaid on a laboratory scene with vials, pipettes, and a computer screen showing a protein model.
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
By Jeffrey Neal Johnson | October 2, 2026
Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$98.86 +0.93 (+0.95%)
As of 09:58 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas